Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand

Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis,...

Full description

Saved in:
Bibliographic Details
Published inBMC infectious diseases Vol. 21; no. 1; pp. 1213 - 9
Main Authors Lerdsamran, Hatairat, Mungaomklang, Anek, Iamsirithaworn, Sopon, Prasertsopon, Jarunee, Prasert, Kriengkrai, Intalapaporn, Poj, Siriyakorn, Nirada, Wiriyarat, Witthawat, Thinpan, Nattakan, Sawadpongpan, Suteema, Sirikhetkon, Somrak, Mongkalangoon, Noparat, Petto, Suwanna, Puthavathana, Pilaipan
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 06.12.2021
BioMed Central
BMC
Subjects
Antibodies
Antibody detection
Antigens
Architects
Assaying
Chemiluminescence assay
Coronaviruses
COVID-19
Disease control
ELISA
Enzyme-linked immunosorbent assay
Epidemics
Immunofluorescence
Immunoglobulin G
Immunology
Infections
Informed consent
Laboratories
Microneutralization assay
Performance evaluation
Proteins
Public health
Respiratory diseases
SARS-coronavirus-2
Sensitivity analysis
Seroepidemiology
Serology
Severe acute respiratory syndrome coronavirus 2
Testing
Travellers
Viral antibodies
Viral diseases
Viruses
Thailand
Beijing China
United States > US
China
Antibody detection
Microneutralization assay
SARS-coronavirus-2
Chemiluminescence assay
ELISA
Online AccessGet full text
ISSN1471-2334
1471-2334
DOI10.1186/s12879-021-06921-y

Cover

Abstract Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
AbstractList Abstract Background Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. Methods This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. Results The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. Conclusions High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation.BACKGROUNDAntibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation.This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection.METHODSThis study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection.The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays.RESULTSThe analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays.High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.CONCLUSIONSHigh-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
Background Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. Methods This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. Results The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. Conclusions High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
Background Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. Methods This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. Results The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. Conclusions High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility. Keywords: SARS-coronavirus-2, Antibody detection, Microneutralization assay, ELISA, Chemiluminescence assay
ArticleNumber 1213
Audience Academic
Author Iamsirithaworn, Sopon
Mongkalangoon, Noparat
Siriyakorn, Nirada
Puthavathana, Pilaipan
Petto, Suwanna
Intalapaporn, Poj
Mungaomklang, Anek
Lerdsamran, Hatairat
Sawadpongpan, Suteema
Prasertsopon, Jarunee
Thinpan, Nattakan
Prasert, Kriengkrai
Wiriyarat, Witthawat
Sirikhetkon, Somrak
Author_xml – sequence: 1
  givenname: Hatairat
  surname: Lerdsamran
  fullname: Lerdsamran, Hatairat
– sequence: 2
  givenname: Anek
  surname: Mungaomklang
  fullname: Mungaomklang, Anek
– sequence: 3
  givenname: Sopon
  surname: Iamsirithaworn
  fullname: Iamsirithaworn, Sopon
– sequence: 4
  givenname: Jarunee
  surname: Prasertsopon
  fullname: Prasertsopon, Jarunee
– sequence: 5
  givenname: Kriengkrai
  surname: Prasert
  fullname: Prasert, Kriengkrai
– sequence: 6
  givenname: Poj
  surname: Intalapaporn
  fullname: Intalapaporn, Poj
– sequence: 7
  givenname: Nirada
  surname: Siriyakorn
  fullname: Siriyakorn, Nirada
– sequence: 8
  givenname: Witthawat
  surname: Wiriyarat
  fullname: Wiriyarat, Witthawat
– sequence: 9
  givenname: Nattakan
  surname: Thinpan
  fullname: Thinpan, Nattakan
– sequence: 10
  givenname: Suteema
  surname: Sawadpongpan
  fullname: Sawadpongpan, Suteema
– sequence: 11
  givenname: Somrak
  surname: Sirikhetkon
  fullname: Sirikhetkon, Somrak
– sequence: 12
  givenname: Noparat
  surname: Mongkalangoon
  fullname: Mongkalangoon, Noparat
– sequence: 13
  givenname: Suwanna
  surname: Petto
  fullname: Petto, Suwanna
– sequence: 14
  givenname: Pilaipan
  surname: Puthavathana
  fullname: Puthavathana, Pilaipan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34872510$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1r2zAUhs3oWD-2P7CLYdjNBnMnybI-bgahdFugUGi63QpZlhIFx-okOSz_fqdJszVljFkgm-PnfaVzeE-LoyEMtiheY3SOsWAfEyaCywoRXCEmYd88K04w5bgidU2PHn0fF6cpLRHCXBD5ojiuqeCkweikMJdr3Y86-zCUwZWdd85GO-TyrtfZhbhKJexlXtiys9maPaiH7KvZ5GZWmhDDoNc-jqki23obOm_Th_J2oX2vh-5l8dzpPtlXD--z4tvny9uLr9XV9ZfpxeSqMqzGuaK2aySnLSGWUSyMcJ2oDdeENE5LygnTDbe4llg6RFsqG0GFNIgKwxiXrD4rpjvfLuiluot-peNGBe3VthDiXOmYvemtooxzzBA8WlMqbCsEEY1uCEaCyVaA16ed193YrmxnYCRR9wemh38Gv1DzsFaCUfCVYPDuwSCGH6NNWa18MraHgdgwJkUY4o2QtWgAffsEXYYxDjAqoDAmjEB_f6i5hgb84AKca-5N1YTBqaSBHoA6_wsFq7MrbyA_zkP9QPD-QABMtj_zXI8pqens5v_Z6--H7JvHA_w9uX30ABA7wMSQUrROGZ-3QYQb-15hpO5TrnYpV5BytU252oCUPJHu3f8h-gWNZ_o5
CitedBy_id crossref_primary_10_1371_journal_pone_0298033
crossref_primary_10_1371_journal_pone_0263316
crossref_primary_10_5937_serbjph2204440K
Cites_doi 10.1093/clinchem/hvaa210
10.1038/s41591-020-0949-6
10.1016/j.jcv.2020.104540
10.1093/infdis/jiaa467
10.1038/s41467-021-22034-1
10.1001/jama.2020.8259
10.1126/science.abc5902
10.1016/S1473-3099(20)30634-4
10.1016/j.jcv.2020.104394
10.1016/j.jcv.2020.104569
10.3390/vaccines9010013
10.1128/JVI.79.6.3289-3296.2005
10.1186/s12985-018-1074-8
10.1093/ofid/ofab239
10.1515/cclm-2020-1413
10.1038/s41467-020-17317-y
10.1038/s41586-020-2912-6
10.1371/journal.pone.0244126
10.46234/ccdcw2020.085
10.3390/v13020247
10.1056/NEJMoa2026116
10.1016/j.eclinm.2020.100651
10.1126/sciimmunol.abc8413
10.1016/j.bbrc.2020.04.136
10.1126/science.abc6952
10.1093/cid/ciaa310
10.1093/infdis/jiaa273
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
NPM
IOV
ISR
3V.
7QL
7T2
7U9
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12879-021-06921-y
DatabaseName CrossRef
PubMed
Gale In Context Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

PubMed


MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1471-2334
EndPage 9
ExternalDocumentID oai_doaj_org_article_4677160000aa448eb88285a5210869b8
PMC8646009
A686425882
34872510
10_1186_s12879_021_06921_y
Genre Journal Article
GeographicLocations Thailand
Beijing China
United States--US
China
GeographicLocations_xml – name: Thailand
– name: China
– name: Beijing China
– name: United States--US
GrantInformation_xml – fundername: National Research Council of Thailand
  grantid: NRCT 11/2563
– fundername: National Science and Technology Development
  grantid: P-17-50551
– fundername: ;
  grantid: NRCT 11/2563
– fundername: ;
  grantid: P-17-50551
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IOV
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
NPM
PMFND
7QL
7T2
7U9
7XB
8FK
AZQEC
C1K
COVID
DWQXO
H94
K9.
M7N
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c631t-4ed5974b22e6418c8fd83c7a225fa94726a57e13919f04b4958489c048c667963
IEDL.DBID M48
ISSN 1471-2334
IngestDate Wed Aug 27 01:29:49 EDT 2025
Thu Aug 21 14:26:39 EDT 2025
Sun Aug 24 04:10:39 EDT 2025
Fri Jul 25 09:50:05 EDT 2025
Tue Jun 17 21:28:28 EDT 2025
Tue Jun 10 20:45:30 EDT 2025
Fri Jun 27 04:58:36 EDT 2025
Fri Jun 27 03:33:39 EDT 2025
Thu Jan 02 22:56:02 EST 2025
Tue Jul 01 03:10:34 EDT 2025
Thu Apr 24 23:11:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Antibody detection
Microneutralization assay
SARS-coronavirus-2
Chemiluminescence assay
ELISA
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c631t-4ed5974b22e6418c8fd83c7a225fa94726a57e13919f04b4958489c048c667963
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2611262667?pq-origsite=%requestingapplication%
PMID 34872510
PQID 2611262667
PQPubID 42582
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_4677160000aa448eb88285a5210869b8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8646009
proquest_miscellaneous_2607589385
proquest_journals_2611262667
gale_infotracmisc_A686425882
gale_infotracacademiconefile_A686425882
gale_incontextgauss_ISR_A686425882
gale_incontextgauss_IOV_A686425882
pubmed_primary_34872510
crossref_citationtrail_10_1186_s12879_021_06921_y
crossref_primary_10_1186_s12879_021_06921_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-06
PublicationDateYYYYMMDD 2021-12-06
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-06
  day: 06
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC infectious diseases
PublicationTitleAlternate BMC Infect Dis
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References L Riepler (6921_CR12) 2020; 9
L Weidner (6921_CR18) 2020; 129
6921_CR20
6921_CR25
J Wu (6921_CR8) 2021; 12
X Xu (6921_CR13) 2020; 26
PJM Brouwer (6921_CR27) 2020; 369
H Lerdsamran (6921_CR19) 2018; 15
K Oved (6921_CR21) 2020; 29
The National SARS-CoV-2 Serology Assay Evaluation Group (6921_CR16) 2020; 20
6921_CR3
W Zeng (6921_CR1) 2020; 527
L Premkumar (6921_CR2) 2020; 5
MK Bohn (6921_CR4) 2020; 58
L Guo (6921_CR6) 2020; 71
D Stadlbauer (6921_CR14) 2021; 590
N Sethuraman (6921_CR5) 2020; 323
DF Gudbjartsson (6921_CR15) 2020; 383
S Nicholson (6921_CR22) 2021; 8
X Chi (6921_CR28) 2020; 369
A Krüttgena (6921_CR17) 2020; 128
GJ Walker (6921_CR11) 2021; 13
K Bond (6921_CR23) 2020; 222
CT Keng (6921_CR29) 2005; 79
CH GeurtsvanKessel (6921_CR10) 2020; 11
N Post (6921_CR7) 2020; 15
E Brochot (6921_CR26) 2020; 130
G Xu (6921_CR24) 2020
PD Burbelo (6921_CR9) 2020; 222
References_xml – year: 2020
  ident: 6921_CR24
  publication-title: Clin Chem
  doi: 10.1093/clinchem/hvaa210
– volume: 26
  start-page: 1193
  issue: 8
  year: 2020
  ident: 6921_CR13
  publication-title: Nat Med
  doi: 10.1038/s41591-020-0949-6
– volume: 129
  start-page: 104540
  year: 2020
  ident: 6921_CR18
  publication-title: J Clin Virol
  doi: 10.1016/j.jcv.2020.104540
– volume: 222
  start-page: 1280
  issue: 8
  year: 2020
  ident: 6921_CR23
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa467
– volume: 12
  start-page: 1813
  issue: 1
  year: 2021
  ident: 6921_CR8
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-22034-1
– volume: 323
  start-page: 2249
  issue: 22
  year: 2020
  ident: 6921_CR5
  publication-title: JAMA
  doi: 10.1001/jama.2020.8259
– volume: 369
  start-page: 643
  issue: 6504
  year: 2020
  ident: 6921_CR27
  publication-title: Science
  doi: 10.1126/science.abc5902
– volume: 20
  start-page: 1390
  issue: 12
  year: 2020
  ident: 6921_CR16
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(20)30634-4
– volume: 128
  start-page: 104394
  year: 2020
  ident: 6921_CR17
  publication-title: J Clin Virol
  doi: 10.1016/j.jcv.2020.104394
– volume: 130
  start-page: 104569
  year: 2020
  ident: 6921_CR26
  publication-title: J Clin Virol
  doi: 10.1016/j.jcv.2020.104569
– volume: 9
  start-page: 13
  issue: 1
  year: 2020
  ident: 6921_CR12
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines9010013
– volume: 79
  start-page: 3289
  issue: 6
  year: 2005
  ident: 6921_CR29
  publication-title: J Virol
  doi: 10.1128/JVI.79.6.3289-3296.2005
– volume: 15
  start-page: 158
  issue: 1
  year: 2018
  ident: 6921_CR19
  publication-title: Virol J
  doi: 10.1186/s12985-018-1074-8
– ident: 6921_CR20
– volume: 8
  start-page: ofab239
  issue: 7
  year: 2021
  ident: 6921_CR22
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofab239
– volume: 58
  start-page: 2001
  issue: 12
  year: 2020
  ident: 6921_CR4
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm-2020-1413
– volume: 11
  start-page: 3436
  issue: 1
  year: 2020
  ident: 6921_CR10
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-17317-y
– ident: 6921_CR3
– volume: 590
  start-page: 146
  issue: 7844
  year: 2021
  ident: 6921_CR14
  publication-title: Nature
  doi: 10.1038/s41586-020-2912-6
– volume: 15
  start-page: e0244126
  issue: 12
  year: 2020
  ident: 6921_CR7
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0244126
– ident: 6921_CR25
  doi: 10.46234/ccdcw2020.085
– volume: 13
  start-page: 247
  issue: 2
  year: 2021
  ident: 6921_CR11
  publication-title: Viruses
  doi: 10.3390/v13020247
– volume: 383
  start-page: 1724
  issue: 18
  year: 2020
  ident: 6921_CR15
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2026116
– volume: 29
  start-page: 100651
  year: 2020
  ident: 6921_CR21
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2020.100651
– volume: 5
  start-page: eabc8413
  issue: 48
  year: 2020
  ident: 6921_CR2
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abc8413
– volume: 527
  start-page: 618
  issue: 3
  year: 2020
  ident: 6921_CR1
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2020.04.136
– volume: 369
  start-page: 650
  issue: 6504
  year: 2020
  ident: 6921_CR28
  publication-title: Science
  doi: 10.1126/science.abc6952
– volume: 71
  start-page: 778
  issue: 15
  year: 2020
  ident: 6921_CR6
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa310
– volume: 222
  start-page: 206
  issue: 2
  year: 2020
  ident: 6921_CR9
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa273
SSID ssj0017829
Score 2.331562
Snippet Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they...
Background Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of...
Abstract Background Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1213
SubjectTerms Antibodies
Antibody detection
Antigens
Architects
Assaying
Chemiluminescence assay
Coronaviruses
COVID-19
Disease control
ELISA
Enzyme-linked immunosorbent assay
Epidemics
Immunofluorescence
Immunoglobulin G
Immunology
Infections
Informed consent
Laboratories
Microneutralization assay
Performance evaluation
Proteins
Public health
Respiratory diseases
SARS-coronavirus-2
Sensitivity analysis
Seroepidemiology
Serology
Severe acute respiratory syndrome coronavirus 2
Testing
Travellers
Viral antibodies
Viral diseases
Viruses
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9BLaZM-3CZFLYUeWpG1LcvScVsS0kJayCYlNyFppWQh2CH2FvLvMyM_WFOaXnrxwRqBPQ_NN_boEyEfLOR0n4mCuTyzjBfKMcO9Y8r40gdIQMbgBueTH-L4nH-_KC42jvrCnrCOHrhT3AEEMkB6XFaNgVLCW4mcawayDoBxZeM2X8h5QzHV_z-AvKeGLTJSHDSwCpeKYTvCTCi43k3SUGTr_3NN3khK04bJjQx09JQ86aEjnXeP_Iw88tUO2T7pf47vEnc4MnfTOtDh6JOW3lybFrFpQ-FKAfHRpW9jC1YUBN2u2GJ-uqAO6QzM79XtumFZvG9r7DL8TM-uzAp7IJ-T86PDs6_HrD9DgTmRpy3jfoklgwWLCJ5KJ8NS5q40EMbBKF5mwhSlBxiYqjDjFsolyaVyENdO4Cem_AXZqurKvyI05SYPMrcwpLgwRlpuQ-GsCiGV1pUJSQeVatcTjOM5F9c6FhpS6M4MGsygoxn0XUI-jXNuOnqNB6W_oKVGSaTGjjfAYXTvMPpfDpOQ92hnjeQXFXbXXJp10-hvP3_puZBQjhUw4W9Ci9OJ0MdeKNTwos70OxpAXUiqNZHcm0hCCLvp8OBzul9CGg2lbZpBuSlAse_GYZyJbXGVr9coA4gPEKcsEvKyc9FROTmUogBeZwkpJ8470d50pFpdRYJxeC5QoHr9P9T9hjzOMO6wA0jska32du33Ace19m0M2XvBY0As
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Public Health Database
  dbid: 8C1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ha9UwEA86QQQRnTqrU6IIftCw1zZNk0_yHBtTmMLeJvsWkrx0ezDa52ufsP_euzSvroj70g_NFdq73N3v0ssvhLy3kNN9Jgrm8swyXijHDPeOKeNLX0ECMgY3OB9_F0dn_Nt5cR4X3NrYVrmJiSFQzxuHa-R7gPTTDNC3KD8vfzE8NQr_rsYjNO6SeynEYOTOl_tDi0cK2U9tNspIsddCLC4Vw6aEiVBwvR4lo8DZ_29kvpGaxm2TN_LQ4WPyKAJIOu0t_oTc8fU2uX8cf5Fvk4f9Qhzt9xc9Je5g4POmTUU3B6J0dHllOkSsLYUrBRxI574LjVlBEDS-YLPpyYw6JDkwvxerdcuycN822Hv4iZ5emgV2Rj4jZ4cHp_tHLJ6swJzI045xP8dCwoKdBE-lk9Vc5q404NyVUbzMhClKD-AwVdWEWyiiJJfKgbc7gQtP-XOyVTe1f0Foyk1eydzCkOLCGGm5rQpnVVWl0royIelGxdpF2nE8_eJKh_JDCt2bRYNZdDCLvk7Ix-GZZU-6cav0F7TcIImE2eFGs7rQ0f805AOoDDE7GwMVqbcSqfsMgBeo6ZSVCXmHdtdIiVFjz82FWbet_vrjp54KCUVaAQ_8T2h2MhL6EIWqBj7UmbjPAdSFVFsjyd2RJDi2Gw9v5qCOgaXVf90gIW-HYXwSm-Vq36xRBnAg4FBZJGSnn7KDcnIoUAHSThJSjibzSHvjkXpxGWjH4b1Agerl7a_1ijzI0MOw40fskq1utfavAbd19k1wzj-w7z6G
  priority: 102
  providerName: ProQuest
Title Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
URI https://www.ncbi.nlm.nih.gov/pubmed/34872510
https://www.proquest.com/docview/2611262667
https://www.proquest.com/docview/2607589385
https://pubmed.ncbi.nlm.nih.gov/PMC8646009
https://doaj.org/article/4677160000aa448eb88285a5210869b8
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf2ISFeEN90G1VASIAgo0kcx35AqJ06DaQO1K6o4sWyXaerVCWjSRH977lzk7KIgXjxQ3yumjtf7n7J-XeEvNAQ023IYt9EofZpLIyvqDW-UDaxKQQgpfCA8-CcnY3pp0k82SF1u6NKgcWN0A77SY2Xi-Of39cfwOHfO4fn7F0Bz9hE-Fhs0GECxvUu2YfIlGArhwH9_VUBoqFwp42SwA-jiNaHaG78jUagcnz-fz61r4WtZknltRh1epfcqZJLr7vZDffIjs3uk1uD6vP5AzLrb7m9vTz16uYopXe1UCVmr4UHowc5oTe1pSvScoKg_bk_6g5HnkHCA_VjvlwVfuiu6xzrEN96F5dqjlWSx6-81w_J-LR_cXLmV50WfMOioPSpnSKw0GA3RgNueDrlkUkUOHuqBE1CpuLEQrIYiLRDNYAqTrkw4P2G4Yuo6BHZy_LMPiFeQFWU8kjDlKBMKa6pTmOjRZoGXJukRYJardJUNOTYDWMhHRzhTG5MIcEU0plCrlvkzXbN1YaE45_SPbTWVhIJtN2FfDmTlT9KiA-AFDFaKwUI1WqOVH4KkhnAeELzFnmOtpZIkZFhDc5MrYpCfvz8VXYZB9AWw4K_CY2GDaGXlVCaw40aVZ17AHUh9VZD8qghCY5umtP1vpO1n0gAwEEIoJSBYp9tp3ElFs9lNl-hDOSFkJfyuEUeb7bpVjkRAFZIcTstkjQ2cEN7zZlsfuloyOF_gQLFwf8o4ZDcDtG3sA6IHZG9crmyTyGbK3Wb7CaTBEZ-ErTJfq9__mXYdm9G2s55YRz2vv0CEQ1HJw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkAAJIRhfhQEGgXiAaE3iOPYDQmVsatk6pK1DezO262yVpqQ0Kaj_FH8jd_liEWJve8lDfK7cu_Pd75zzHSGvDfh0F_DIs2FgPBZJ62nmrCe1i10CDkhrvOA8PuDDY_blJDpZI7-buzCYVtnYxNJQTzOLZ-RbgPT9ANA3jz_Of3jYNQq_rjYtNCq12HOrXxCy5R9Gn0G-b4Jgd2eyPfTqrgKe5aFfeMxNEUQbWCNnvrAimYrQxhoUO9GSxQHXUewAGPky6TMDAYRgQlrQdMvx0CWE371GrrMwjLFWv9huU0p88LayuZgj-FYOtj-WHiZB9LmE56rj_MoeAf96gguusJumecHv7d4ld2rASgeVht0jay7dIDfG9Sf5DXK7Ovij1X2m-8TutPXDaZbQpgFLQefnukCEnFN4UsCddOqKMhGsJAQJz7yjweERtVhUQf-cLZa5F5TvTYa5ju_p5EzPMBPzATm-Ep4_JOtplrrHhPpMh4kIDQxJxrUWhpkkskYmiS-MjXvEb1isbF3mHLttnKsy3BFcVWJRIBZVikWteuRdO2deFfm4lPoTSq6lxALd5Ytscarq_a7A_0AkimhAa4iAnRFYKlADWIIYUhrRI69Q7gpLcKSY43Oql3muRl-_qQEXEBRGMOF_REeHHaK3NVGSwR-1ur5XAezC0l4dys0OJRgS2x1udFDVhixXf7ddj7xsh3EmJuelLlsiDeBOwL0i6pFHlcq2zAkhIAYI3e-RuKPMHe51R9LZWVnmHNYFDJRPLl_WC3JzOBnvq_3Rwd5TcivA3YbZRnyTrBeLpXsGmLEwz8uNSsn3q7YMfwByrnjy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+different+platforms+for+the+detection+of+anti-SARS+coronavirus-2+antibodies%2C+Thailand.%28+%29&rft.jtitle=BMC+infectious+diseases&rft.au=Lerdsamran%2C+Hatairat&rft.au=Mungaomklang%2C+Anek&rft.au=Iamsirithaworn%2C+Sopon&rft.au=Prasertsopon%2C+Jarunee&rft.date=2021-12-06&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-021-06921-y&rft.externalDBID=ISR&rft.externalDocID=A686425882
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon